PubMed Health⌕ Search

PubMed · 15244721

Three-dimensional simulation of square jets in cross-flow.

Abstract

Direct numerical simulations are performed to predict the three-dimensional unsteady flow interactions in the near-field of a square jet issuing normal to a cross-flow. The simulated flow features reveal the formation of an upstream horseshoe vortex system, which is the result of an interaction between the oncoming channel floor shear layer and the transverse jet; the growth of a sequence of Kelvin-Helmholtz instability-induced vortical rollers in the mixing layer between the jet and the cross-flow, which wrap around the front side of the jet; and the inception process of the counter-rotating vortex pair (CVP), which is initiated through the folding of the lateral jet shear layers. It has been observed that for a square jet in cross-flow, the developed Kelvin-Helmholtz instability induced shear layer rollers do not form closed circumferential vortex rings. Along the downstream side of the jet, the extended tails of such rollers gradually join the locally evolving CVP. The very inception of the CVP is, however, observed to take place within the cross-flow-induced skewed lateral jet shear layers, and such inception was seen to occur slightly below the jet orifice. The simulated results also reveal the growth of the upright wake vortices from the topological singular points that developed on the cross-flow floor boundary layer. The accumulated floor vortices are seen to spiral around the critical points and subsequently leave the channel floor uprightly. During upward motion these vortices eventually get entrained into the CVP core. It has been made clear topologically that the unstable local surface excitations are the seeds from which upright vortices grow. Interestingly, such findings remain quite consistent with the existing experimental predictions for a round jet. Simulations were performed for two moderate values of the Reynolds number 225 and 300, based on the jet width and the average cross-flow inlet velocity, and for two different values of the jet to cross-stream velocity ratio, 2.5 and 3.5.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Amalendu Sau, Tony W H Sheu, Robert R Hwang, W C Yang. 2004-06-04. Three-dimensional simulation of square jets in cross-flow.. https://doi.org/10.1103/physreve.69.066302

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗